

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CONCORD HEALTHCARE GROUP CO., LTD.

美中嘉和醫學技術發展集團股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2453)

CHANGE OF EXECUTIVE DIRECTOR

The Board hereby announces that, on April 8, 2026, in line with the Company's strategic development plan and succession plan, Ms. Fu Xiao has tendered her resignation as a director of the Company and will assume the role of advisor to the Company as she has reached the retirement age. The aforesaid resignation of Ms. Fu Xiao will take effect upon the new executive Director being elected by the Shareholders at the AGM.

On April 8, 2026, the Board nominated Mr. Jiang Wei as an executive Director. The proposed appointment of Mr. Jiang Wei as an executive Director is subject to the approval by the Shareholders at the AGM in accordance with the articles of association of the Company.

A circular of the Company containing detailed information in relation to the above-mentioned proposal will be dispatched to the Shareholders in due course.

RESIGNATION OF EXECUTIVE DIRECTOR

Recently, the board (the "**Board**") of directors (the "**Directors**") of Concord Healthcare Group Co., Ltd. (the "**Company**") received a resignation letter from Ms. Fu Xiao ("**Ms. Fu**"), informing the Board of her resignation from the position as an executive Director as she has reached the retirement age. The aforesaid resignation of Ms. Fu will take effect upon the new executive Director being elected by the shareholders of the Company (the "**Shareholders**") at the annual general meeting to be held on May 11, 2026 (the "**AGM**").

Ms. Fu has confirmed that she has no disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited (the "**Hong Kong Stock Exchange**") and the Shareholders.

The Board would like to take this opportunity to express its sincere gratitude to Ms. Fu for her contributions to the development of the Company during her term of office.

PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR

The Board further announces that, on April 8, 2026, the Board proposed to appoint Mr. Jiang Wei (姜偉) (“**Mr. Jiang**”) as an executive Director. The proposed appointment is subject to the approval by the Shareholders at the AGM in accordance with the articles of association of the Company. The terms of office of Mr. Jiang will commence from the date of approval at the AGM until the expiration of the term of the fourth session of the Board.

Biographical details of Mr. Jiang

Mr. Jiang, aged 45, is the President of the Company. Mr. Jiang joined the Group in 2020. From June 2020 to date, Mr. Jiang has been serving as the chief executive officer and a director of Beijing Healthingkon Technology Co., Ltd. (北京和信康科技有限公司), the principal AI business entity of the Group, and has successively served as the chairman of Shanghai Concord Medical Diagnostic Imaging Limited (上海美中嘉和醫學影像診斷有限公司), a director of Guangzhou Concord Cancer Center Co., Ltd. (廣州泰和腫瘤醫院有限公司), a director of Shanghai Concord Medical Cancer Hospital Limited (上海泰和誠腫瘤醫院有限公司), and the chief financial officer of Concord Medical Services Holdings Limited.

Prior to joining the Group, he worked at Ernst & Young from July 2003 to June 2007. From July 2007 to May 2020, he was employed by China International Capital Corporation Limited, during which he served in various departments, including the Planning and Analysis Department, the Investment Banking Department and CICC Capital.

Mr. Jiang obtained his Bachelor of Finance degree from the School of Economics of Peking University in 2003 and an MBA degree from Guanghua School of Management, Peking University in July 2012.

Mr. Jiang as an executive Director of the Company and the President, will focus on the principal business of oncology diagnosis and treatment in the future. He will further integrate the Group’s strengths in clinical capabilities and data resources with AI technologies, continue to lead the team in deepening its presence in the field of AI-enabled oncology diagnosis and treatment, and actively expand overseas businesses, thereby consolidating the Group’s leading position in the industry.

Upon the appointment of Mr. Jiang as an executive Director being approved by the Shareholders at AGM, the Company will enter into a service contract with Mr. Jiang. Mr. Jiang’s remuneration as an executive director will be determined in accordance with the remuneration policy to be approved at the AGM for the year ended December 31, 2025, the details can be referred to in the annual report to be released by the Company in due course.

Save as disclosed in this announcement, as at the date of this announcement, Mr. Jiang:

- (i) has not held any other major appointments or qualifications or directorships in other listed companies during the past three years preceding the date of this announcement;
- (ii) does not have any relationship with any Director, senior management, substantial or controlling Shareholder (having the meaning ascribed to it in the Listing Rules) of the Company;
- (iii) does not hold other positions with the Company or other members of the Group; and
- (iv) is not interested in any shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571).

Save as disclosed in this announcement, the Board is not aware of any other matters in relation to Mr. Jiang's appointment as an executive Director that need to be brought to the attention of the Shareholders nor any information that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

A circular of the Company containing detailed information in relation to the above-mentioned proposal will be dispatched to Shareholders in due course.

By Order of the Board
Concord Healthcare Group Co., Ltd.
YANG Jianyu
Chairman of the Board and Executive Director

Beijing, the PRC, April 8, 2026

As at the date of this announcement, the Board comprises (i) Dr. YANG Jianyu, Ms. FU Xiao and Mr. CHANG Liang as executive Directors; (ii) Mr. WANG Lei, Mr. SONG Qingbao and Mr. SHI Botao as non-executive Directors; and (iii) Ms. LI Xuemei, Mr. SUN Yansheng and Mr. NG Kwok Yin as independent non-executive Directors.